HUP9904243A2 - Eljárás a Fas expressziójának gátlására - Google Patents

Eljárás a Fas expressziójának gátlására

Info

Publication number
HUP9904243A2
HUP9904243A2 HU9904243A HUP9904243A HUP9904243A2 HU P9904243 A2 HUP9904243 A2 HU P9904243A2 HU 9904243 A HU9904243 A HU 9904243A HU P9904243 A HUP9904243 A HU P9904243A HU P9904243 A2 HUP9904243 A2 HU P9904243A2
Authority
HU
Hungary
Prior art keywords
hydrogen atom
alkyl
ring
pipe powder
atom
Prior art date
Application number
HU9904243A
Other languages
English (en)
Inventor
Giora Zeev Feuerstein
Tian-Li Yue
Original Assignee
Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Partnership No. 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Partnership No. 1 filed Critical Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Partnership No. 1
Publication of HUP9904243A2 publication Critical patent/HUP9904243A2/hu
Publication of HUP9904243A3 publication Critical patent/HUP9904243A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)

Abstract

A találmány kettős nemszelektív b-adrenőceptőr és al-adreceptőrantagőnista vegyületeknek, különösen az (I) általánős képletű[(4-karbazőlil-őxi]-prőpanől-amin-vegyületeknek (l) - amelyek képletében R7-R13 mindegyikének jelentése hidrőgénatőm vagv hidrőxicsőpőrt, és A(II) általánős képletű csőpőrt, (II) ahől R1 hidrőgénatőm, alkanőil-, benzőil-, naftőilcsőpőrt, R2 hidrőgénatőm, alkil-, benzil-, fenil-etil-, fenil-prőpek-csőpőrt, R3 hidrőgénatőm vagy alkilcsőpőrt, R4 hidrőgénatőm vagy alkilcsőpőrt, vagy ha X őxigénatőm, R4 és R5együtt -CH2-O- képletű csőpőrtőt képezhet, X egyes kötés, metiléncsőpőrt, őxigén- vagy kénatőm, Ar fenil-, naftil-, indanil-, tetrahidrőnaftilcsőpőrt, R5 és R6, hidrőgén-, tlűőr-, klór-, brómatőm-, hidrőxi-, alkil-, -CONH2-, alkőxi-, benzil-őxi-, alkil-tiő-, alkil-szűlfinil- vagy alkil-szűlfőnilcsőpőrt, vagy R5 és R6 együtt metilén-diőxi-csőpőrtőt képez -vagy gyógyászatilag elfőgadható sóiknak, előnyösen carvedilőlnak a Fassejtfelületi prőtein expressziójának gátlására történő alkalmazásáravőnatkőzik. ŕ
HU9904243A 1996-08-23 1997-08-22 Method for inhibiting the expression of fas HUP9904243A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2448696P 1996-08-23 1996-08-23

Publications (2)

Publication Number Publication Date
HUP9904243A2 true HUP9904243A2 (hu) 2000-05-28
HUP9904243A3 HUP9904243A3 (en) 2001-09-28

Family

ID=21820837

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904243A HUP9904243A3 (en) 1996-08-23 1997-08-22 Method for inhibiting the expression of fas

Country Status (17)

Country Link
US (1) US6096777A (hu)
EP (1) EP0924985A4 (hu)
JP (1) JP2001504804A (hu)
KR (1) KR20000068322A (hu)
CN (1) CN1233150A (hu)
AU (1) AU4083097A (hu)
BR (1) BR9711228A (hu)
CA (1) CA2264178A1 (hu)
CZ (1) CZ59199A3 (hu)
HU (1) HUP9904243A3 (hu)
IL (1) IL128613A (hu)
NO (1) NO990792L (hu)
NZ (1) NZ334307A (hu)
PL (1) PL331766A1 (hu)
TR (1) TR199900370T2 (hu)
WO (1) WO1998007321A1 (hu)
ZA (1) ZA977565B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
CN1678305A (zh) * 2002-06-27 2005-10-05 Sb药物波多黎各公司 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2002336473A1 (en) * 2002-09-10 2004-04-30 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
ZA200803226B (en) 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation

Also Published As

Publication number Publication date
EP0924985A4 (en) 2000-12-06
CZ59199A3 (cs) 1999-08-11
HUP9904243A3 (en) 2001-09-28
TR199900370T2 (xx) 1999-05-21
NZ334307A (en) 2000-11-24
JP2001504804A (ja) 2001-04-10
NO990792D0 (no) 1999-02-19
PL331766A1 (en) 1999-08-02
WO1998007321A1 (en) 1998-02-26
NO990792L (no) 1999-04-15
CN1233150A (zh) 1999-10-27
KR20000068322A (ko) 2000-11-25
AU4083097A (en) 1998-03-06
IL128613A0 (en) 2000-01-31
BR9711228A (pt) 2000-01-11
US6096777A (en) 2000-08-01
IL128613A (en) 2004-07-25
EP0924985A1 (en) 1999-06-30
CA2264178A1 (en) 1998-02-26
ZA977565B (en) 1999-02-17

Similar Documents

Publication Publication Date Title
HUP9904243A2 (hu) Eljárás a Fas expressziójának gátlására
HUP0303081A2 (hu) Trombin receptor antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
HUP9800634A2 (hu) p-Amidino-benzil-amid-származék trombin-inhibitorok, intermedierjeik és alkalmazásuk
AU3110999A (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
TR199802698T2 (xx) Valsartan�n kat� oral doz formlar�.
IL148932A0 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
YU9802A (sh) Inhibitori ćelijske adhezije
MXPA02003203A (es) Composiciones terapeuticas solubles en tocol.
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
AP2001002309A0 (en) 1-amino triazolo[4,3-A] quinazoline-5-ones and/or-5-thiones inhibiting phosphodiesterase IV.
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
PE46699A1 (es) Compuesto derivado de indol
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
TR200501137T2 (tr) Endotelin antagonistleri.
TR200001452T2 (tr) Bifenilamidin türevleri.
PT1105105E (pt) Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
EA200201149A1 (ru) Фармацевтические композиции и способы для предотвращения рецидива мигрени
AU6220300A (en) Benzofurylpiperazine serotonin agonists